Learn Before
References for New Drug Treatments for Tic Disorders
Gilbert, D. L., Murphy, T. K., Jankovic, J., Budman, C. L., Black, K. J., Kurlan, R. M., Coffman, K. A., McCracken, J. T., Juncos, J., Grant, J. E., & Chipkin, R. E. (2018). Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Movement disorders : official journal of the Movement Disorder Society, 33(8), 1272–1280. https://doi.org/10.1002/mds.27457
0
1
Tags
Psychology
Social Science
Empirical Science
Science
Clinical Practice of Psychology
Neurodevelopmental Disorders
Interdisciplinary Research
OpenStax Psychology (2nd ed.) Textbook
Learn After
Gilbert, D. L., Murphy, T. K., Jankovic, J., Budman, C. L., Black, K. J., Kurlan, R. M., Coffman, K. A., McCracken, J. T., Juncos, J., Grant, J. E., & Chipkin, R. E. (2018). Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Movement disorders : official journal of the Movement Disorder Society, 33(8), 1272–1280. https://doi.org/10.1002/mds.27457
Darwish MK, Nasser M, Mohammed HE, et al. Is Ecopipam an effective treatment for Tourette syndrome? A systematic review and meta-analysis with GRADE assessment. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2026;62:2. DOI: 10.1186/s41983-025-01064-2
Panda, P. K., Panda, P., Dawman, L., Mishra, A. S., Kumar, V., & Sharawat, I. K. (2025). Safety and Efficacy of Ecopipam in Patients with Tourette Syndrome: A Systematic Review and Meta-analysis. CNS drugs, 39(2), 127–142. https://doi.org/10.1007/s40263-024-01140-w
ClinicalTrials.gov. (2024). Efficacy and safety of gemlapodect (NOE-105) in adults and adolescents with Tourette syndrome (Identifier NCT06315751). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT06315751
Noema Pharma AG. (2024a, October 17). Noema Pharma announces NOE-105 (gemlapodect) Phase 2a study in Tourette syndrome met primary and all key secondary endpoints. https://noemapharma.com/2024/10/17/noema-pharma-announces-noe-105-gemlapodect-phase-2a-study-in-tourette-syndrome-met-primary-and-all-key-secondary-endpoints/
Noema Pharma AG. (2024b, October 30). Noema Pharma announces first patients dosed in Phase 2b study with gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette syndrome. https://noemapharma.com/2024/10/30/noema-pharma-announces-first-patients-dosed-in-phase-2b-study-with-gemlapodect-noe-105-a-first-in-class-investigational-therapy-for-tourette-syndrome/
Besag, F. M., Vasey, M. J., Lao, K. S., Chowdhury, U., & Stern, J. S. (2021). Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review. Journal of psychopharmacology (Oxford, England), 35(9), 1037–1061. https://doi.org/10.1177/02698811211032445